Search results for "WEIGHT LOSS"

showing 10 items of 298 documents

Empowering citizens for well-being and chronic disease management with wellness diary.

2010

Chronic conditions closely related to lifestyles are the major cause of disability and death in the developed world. Behavior change is the key to managing well-being and preventing and managing chronic diseases. Wellness diary (WD) is a mobile application designed to support citizens in learning about their behavior, and both making and maintaining behavior changes. WD has been found acceptable, useful, and suitable for long-term use as a part of an intervention. When used independently, however, it does not seem to have enough engaging and motivating features to support adoption and long-term commitment. The main improvement needs identified based on a review of WD-related studies were: p…

Adultself-managementKnowledge managementApplied psychologyMobile computingCognitive-behavior therapyself-observationMedical RecordsPersonalizationBehavior TherapyIntervention (counseling)Health careWeight LossMedicineHumansMedical Informatics ApplicationsElectrical and Electronic EngineeringRisk managementSelf-managementCognitive Behavioral Therapybusiness.industryBehavior changeRehabilitationDisease ManagementGeneral Medicinemobile applicationMiddle AgedModels TheoreticalComputer Science ApplicationsSelf CareWell-beingbusinessSoftwareBiotechnologyIEEE transactions on information technology in biomedicine : a publication of the IEEE Engineering in Medicine and Biology Society
researchProduct

Impact of a program based in eating habits and physiotherapy on anthropometric parameters in patients with coronary artery disease: randomized contro…

2021

Abstract Funding Acknowledgements Type of funding sources: None. Introduction. On the one hand, physical training such as High intensity interval training (HIIT) and on the other, eating habits, it is often prescribed to patients with coronary artery disease (CAD). Nevertheless, the combination of HIIT and eating habits in CAD with percutaneous coronary intervention (PCI) there is no consensus on using a combined protocol of both. Purpose. The purpose of this study was to evaluate the impact of an HIIT program with eating habits, with a program based in HIIT, on anthropometric parameters in CAD patients with PCI. Methods. A randomized controlled trial was carried out in a hospital.  44 pati…

Advanced and Specialized Nursingmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionmedicine.diseaselaw.inventionAnthropometric parametersCoronary artery diseaseMedical–Surgical NursingRandomized controlled trialWeight lossInformed consentlawPhysical therapymedicineIn patientmedicine.symptomCardiology and Cardiovascular MedicineEating habitsbusinessEuropean Journal of Cardiovascular Nursing
researchProduct

The value of neutrophil and lymphocyte count in frail older women.

2013

Increasing evidence suggests that systemic inflammation is associated with many pathophysiological processes including frailty in older adults. We evaluated the relationships between white blood cell subtypes, geriatric assessment, and frailty syndrome and in particular, how they correlate with individual frailty criteria (involuntary loss of weight, low energy or exhaustion, slow mobility, muscle weakness, and low physical activity) in frail older women. There was a significant and positive correlation between the frailty score and neutrophil count, but a significantly negative correlation was found when this score was compared to the lymphocyte count. These associations were significant o…

Agingmedicine.medical_specialtyNeutrophilsLymphocyteFrail ElderlyFrailty syndromePilot ProjectsSystemic inflammationPhysical strengthBiochemistryLeukocyte CountEndocrinologyWeight lossWhite blood cellInternal medicineWeight LossGeneticsmedicineHumansLymphocyte CountLymphocytesMuscle StrengthMolecular BiologyExerciseGeriatric AssessmentAged 80 and overHand Strengthbusiness.industryMuscle weaknessCell Biologymedicine.diseasemedicine.anatomical_structureCross-Sectional StudiesImmune System DiseasesPhysical FitnessPhysical therapyAbsolute neutrophil countFemalemedicine.symptombusinessExperimental gerontology
researchProduct

Ethological analysis of morphine withdrawal with different dependence programs in male mice.

2002

Abstract This work was performed to clarify the differences between a long or short development of morphine dependence as well as between a recently installed or a long-term dependence. Morphine withdrawal in rats is a well-characterized phenomenon but this is not so in mice. A study of the principal withdrawal signs have been performed in mice, evaluating their specificity and particular profile of appearance in each type of dependence. Mice were divided into two groups that received increasing doses of morphine every 24 h, three groups that received increasing doses of morphine twice a day for 3 days, and a control group that received saline. Naloxone-induced opiate withdrawal was evaluat…

AgonistMaleNarcoticsmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPiloerectionMiceOpioid receptorInternal medicineNaloxoneTremorWeight LossmedicineAnimalsSalineBiological PsychiatryPharmacologyBehavior AnimalMorphinebusiness.industryAntagonistEthologyOpioid-Related DisordersSubstance Withdrawal SyndromeEndocrinologyAnesthesiaToxicityMorphinebusinessmedicine.drugProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

Patterns of weight cycling in youth Olympic combat sports: a systematic review

2022

Abstract Background Patterns of weight cycling in adult combat sports have been extensively studied, yet data on this matter in youth combat athletes is rather scarce. Methods PubMed, EBSCOhost and Web of Science were used to retrieve relevant data. Eligible studies had to record the methods used to elicit rapid weight loss (RWL) and/or record the oscillations in bodyweight during the RWL phase. Only studies conducted in the context of an official competition were considered for inclusion in the present review. Results RWL is highly prevalent in children and adolescent combat athletes, ranging from 25 to 94% depending on the type of combat sport, age and level of competition. These athletes…

Behavioral NeurosciencePsychiatry and Mental healthNutrition and DieteticsHealthRapid weight lossPerformanceAdolescents; Children; Health; Performance; Rapid weight gain; Rapid weight lossAdolescentsChildrenRapid weight gain
researchProduct

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

2015

BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive on…

Blood GlucoseCounselingMaleType 2 diabeteslaw.inventionBody Mass IndexRandomized controlled trialWeight losslawGlucagon-Like Peptide 1Weight managementSubcutaneousMedicine (all)ReducingNauseaGeneral MedicineMiddle AgedCombined Modality Therapy3. Good healthFemaletype 2 diabetesmedicine.symptomHumanmedicine.drugAdultDiarrheamedicine.medical_specialtyDiet ReducingInjections SubcutaneousInjections SubcutaneouPlaceboInjectionsDouble-Blind MethodInternal medicineWeight LossmedicineHumansHypoglycemic AgentsObesityExerciseHypoglycemic AgentLiraglutidebusiness.industryLiraglutidemedicine.diseaseWeight LoDietEndocrinologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass index[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDyslipidemiaAdult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Counseling; Diarrhea; Diet Reducing; Double-Blind Method; Exercise; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Nausea; Obesity; Weight Loss; Medicine (all)The New England journal of medicine
researchProduct

Asperuloside Enhances Taste Perception and Prevents Weight Gain in High-Fat Fed Mice

2021

Asperuloside is an iridoid glycoside found in many medicinal plants that has produced promising anti-obesity results in animal models. In previous studies, three months of asperuloside administration reduced food intake, body weight, and adipose masses in rats consuming a high fat diet (HFD). However, the mechanisms by which asperuloside exerts its anti-obesity properties were not clarified. Here, we investigated homeostatic and nutrient-sensing mechanisms regulating food intake in mice consuming HFD. We confirmed the anti-obesity properties of asperuloside and, importantly, we identified some mechanisms that could be responsible for its therapeutic effect. Asperuloside reduced body weight …

Blood GlucoseLeptinMalecannabinoid (CB) receptor 10301 basic medicineTastePro-Opiomelanocortinfood intakeEndocrinology Diabetes and MetabolismAdipose tissueWeight Gainnutrient-sensing mechanismslcsh:Diseases of the endocrine glands. Clinical endocrinologyCyclopentane MonoterpenesEnergy homeostasisMiceEndocrinology0302 clinical medicineGlucosidesWeight lossInsulinasperuloside; cannabinoid (CB) receptor 1; CD36; FFAR1-4; food intake; nutrient-sensing mechanisms; TAS1R2-3; weight lossReceptorOriginal ResearchLeptindigestive oral and skin physiologyTaste PerceptionGhrelinTAS1R2-3Ghrelinmedicine.symptommedicine.medical_specialtyHypothalamusBiologyDiet High-Fatasperuloside03 medical and health sciencesInternal medicinemedicineAnimalsPyranslcsh:RC648-665Body WeightFFAR1-4030104 developmental biologyEndocrinologyAnti-Obesity Agentsweight lossEnergy IntakeCD36Weight gain030217 neurology & neurosurgery
researchProduct

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-…

2017

Background: \ud Liraglutide 3·0 mg was shown to reduce bodyweight and improve glucose metabolism after the 56-week period of this trial, one of four trials in the SCALE programme. In the 3-year assessment of the SCALE Obesity and Prediabetes trial we aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.\ud \ud Methods: \ud In this randomised, double-blind, placebo-controlled trial, adults with prediabetes and a body-mass index of at least 30 kg/m2, or at least 27 kg/m2 with comorbidities, were randomised 2:1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3·0 mg or matched placebo, as an adjunct to a reduced-…

Blood GlucoseMaleEXENATIDEType 2 diabetes030204 cardiovascular system & hematologyBody Mass Indexlaw.inventionPlacebosImpaired glucose toleranceMELLITUS3.0 MG0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawPREVENTION PROGRAM OUTCOMESPrediabetesPREVENTION PROGRAM OUTCOMES; IMPAIRED GLUCOSE-TOLERANCE; LIFE-STYLE; CLINICAL-TRIAL; OBESE SUBJECTS; 3.0 MG; REGRESSION; EXENATIDE; MELLITUSSubcutaneousMedicine (all)General MedicineMiddle AgedAdult; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus Type 2; Double-Blind Method; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Obesity; Placebos; Prediabetic State; Risk Reduction Behavior; Treatment Outcome; Weight Loss3. Good healthTreatment OutcomeFemaleLIFE-STYLEType 2OBESE SUBJECTSmedicine.drugAdultmedicine.medical_specialtyInjections Subcutaneous030209 endocrinology & metabolismPlaceboIncretinsGlucagon-Like Peptide-1 ReceptorInjectionsCLINICAL-TRIALPrediabetic State03 medical and health sciencesIMPAIRED GLUCOSE-TOLERANCEDouble-Blind MethodDiabetes mellitusInternal medicineWeight LossREGRESSIONDiabetes MellitusmedicineHumansHypoglycemic AgentsObesityLiraglutidebusiness.industryBody WeightLiraglutidemedicine.diseaseClinical trialEndocrinologyDiabetes Mellitus Type 2Human medicinebusinessRisk Reduction Behavior[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe Lancet
researchProduct

Effect of a Natural Supplement Containing Curcuma Longa, Guggul, and Chlorogenic Acid in Patients With Metabolic Syndrome

2015

The impact of a natural supplement (Kepar; Rikrea, Italy), containing several plant extracts such as curcuma longa, silymarin, guggul, chlorogenic acid, and inulin, was evaluated in 78 patients with metabolic syndrome (MetS; 45 men; age: 62 ± 9 years). Kepar at a dose of 2 pills/d was given for 4 months as add-on therapy to the ongoing treatment, maintained at fixed doses for the entire study. Anthropometric variables, plasma lipids, glucose parameters, and oxidative stress were measured at baseline and after 4 months. We found significant reductions in body weight (from 81.1 ± 13.5 to 79.4 ± 12.5 kg, P < .0001), body mass index (from 29.6 [23.7] to 29.3 [21.9] kg/m2, P = .001), and wai…

Blood GlucoseMaleTime FactorssilymarinPilot Projectsmedicine.disease_causelaw.inventionchemistry.chemical_compoundlawWeight lossPlant GumsPlant GumCommiphoraCurcuma longainulinbiologyMetabolic Syndrome XMedicine (all)Middle AgedTreatment OutcomeItalyFemalemedicine.symptomCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyTime Factorchlorogenic acidmetabolic syndromePlant ExtractCurcumaChlorogenic acidguggulInternal medicineWeight LossmedicineHumansPilot ProjectCurcumaAgedDietary Supplementoxidative strePlants MedicinalPlant Extractsbusiness.industryCholesterolcholesterolBiomarkerbiology.organism_classificationmedicine.diseaseWeight LoOxidative Stressnatural supplementEndocrinologychemistryDietary SupplementsMetabolic syndromePhytotherapybusinessBody mass indexBiomarkersOxidative stressPhytotherapyAngiology
researchProduct

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

2014

Aim The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone. Methods In this randomized, double-blind, phase 3 study, patients (N = 342) received canagliflozin 100 or 300 mg during a 26-week, placebo-controlled, core period and a 26-week, active-controlled extension in which placebo-treated patients were switched to sitagliptin 100 mg. Efficacy comparisons for canagliflozin versus placebo at week 26 are reported, with no comparisons versus sitagliptin at week 52 (sitagliptin used to maintain double-blind and control for safety). Safety data ar…

Blood GlucoseMaleendocrine system diseasesEndocrinology Diabetes and Metabolismphase 3 studyBlood PressureType 2 diabetesPharmacologyEndocrinologyGlucosidesWeight lossCanagliflozinCandidiasisSGLT2 inhibitorMiddle AgedDiuretics OsmoticLipidsMetforminMetforminTreatment OutcomePyrazinesDrug Therapy CombinationFemaletype 2 diabetesmedicine.symptomSGLT2 InhibitorGenital Diseases Malemedicine.drugmedicine.medical_specialtyUrologyThiophenesDouble-Blind MethodWeight LossInternal MedicinemedicineHumansHypoglycemic AgentsCanagliflozinthiazolidinedionesPioglitazonebusiness.industrySitagliptin Phosphatenutritional and metabolic diseasesType 2 Diabetes MellitusOriginal ArticlesTriazolesmedicine.diseaseBlood pressureDiabetes Mellitus Type 2businessPioglitazoneGenital Diseases FemaleDiabetes, obesitymetabolism
researchProduct